首页> 外文期刊>JGH OPEN >Validation of a novel single‐drop rapid human leukocyte antigen‐DQ2/‐DQ8 typing method to identify subjects susceptible to celiac disease
【24h】

Validation of a novel single‐drop rapid human leukocyte antigen‐DQ2/‐DQ8 typing method to identify subjects susceptible to celiac disease

机译:验证新型单滴快速人类白细胞抗原-DQ2 / -DQ8分型方法以鉴定易患乳糜泻的受试者

获取原文
           

摘要

Background and Aim Human leukocyte antigen (HLA)‐DQ2 and/or ‐DQ8 is an essential risk factor for celiac disease (CD). About 90–95% of patients with CD carry HLA‐DQ2/‐DQ8 alleles, and HLA‐DQ typing is considered an additional diagnostic test. Conventional polymerase chain reaction (PCR)‐based HLA‐DQ typing methods are expensive, complex, and a time‐consuming process. We assessed the efficacy of a novel HLA‐DQ typing method, “Celiac Gene Screen,” for the detection of CD‐associated HLA haplotypes. Methods To assess the diagnostic performance of the Celiac Gene Screen test, 100 ethylenediaminetetraacetic acid (EDTA) blood samples, already characterized by the conventional HLA‐DQ typing method, that is, PCR sequence‐specific oligonucleotide probes (PCR‐SSOP), a concordance between both the methods were explored. For validity, a further 300 EDTA blood samples with unknown HLA‐DQ status were genotyped using the Celiac Gene Screen test, including 141 samples from CD, 56 first‐degree relatives (FDRs) of CD and 103 samples from controls. Results Of the 100 samples with known status of HLA‐DQ alleles, 79 samples were HLA‐DQ2 and/or ‐DQ8 positive, and 21 samples were HLA‐DQ2 and/or ‐DQ8 negative by conventional PCR. These 100 samples were re‐typed using the Celiac Gene screen kit; all 79 positives were typed positive, and 21 negatives were typed negative for HLA‐DQ alleles. Among 300 samples with unknown HLA‐DQ status, 118 of 141 (84%) patients with CD, 48 of 56 (86%) FDRs of CD, and 52 of 103 (50%) controls typed positive for HLA‐DQ alleles. Conclusions The Celiac Gene Screen HLA‐DQ typing method showed excellent concordance with the conventional HLA‐DQ typing method and could be a cost‐reducing and effective method for CD‐associated HLA screening.
机译:背景与目的人白细胞抗原(HLA)‐DQ2和/或‐DQ8是乳糜泻(CD)的重要危险因素。大约90%至95%的CD患者携带HLA-DQ2 / -DQ8等位基因,HLA-DQ分型被认为是一项附加的诊断测试。基于常规聚合酶链反应(PCR)的HLA-DQ分型方法昂贵,复杂且耗时。我们评估了一种新颖的HLA-DQ分型方法“乳糜泻基因筛选”对检测CD相关HLA单倍型的功效。方法为评估乳糜泻基因筛查测试的诊断性能,已通过常规HLA-DQ分型方法表征了100个乙二胺四乙酸(EDTA)血液样本,即采用PCR序列特异性寡核苷酸探针(PCR-SSOP),两种方法之间的探讨。为了验证有效性,使用Celiac基因筛选测试对300例HLA-DQ状况未知的EDTA血液样本进行了基因分型,包括141个CD样本,56个CD一级亲属(FDR)和103个对照样本。结果在100份HLA-DQ等位基因状态已知的样品中,常规PCR检测到79份HLA-DQ2和/或-DQ8阳性,21份HLA-DQ2和/或-DQ8阴性。使用Celiac Gene筛选试剂盒对这100个样品重新打样。 HLA-DQ等位基因的所有79个阳性均为阳性,阴性的21个均为阴性。在300例HLA-DQ状态未知的样本中,CD患者141例中有118例(占84%),CD的FDR中有48例(占86%),而HLA-DQ等位基因阳性则有52例(103%)对照。结论腹腔基因筛查HLA-DQ分型方法与常规HLA-DQ分型方法具有极佳的一致性,可以作为CD相关HLA筛查的一种低成本且有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号